corticosteroids - versus control - for COVID-19 pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.92 [0.67, 1.28]< 10%1 study (1/-)68.5 %some concernnot evaluable moderatecrucial-
deaths 0.92 [0.83, 1.02]< 134%10 studies (10/-)95.0 %some concernlow moderatecrucial-
deaths (time to event analysis only) 0.96 [0.70, 1.31]< 10%2 studies (2/-)60.3 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.67 [0.44, 1.03]< 10%2 studies (2/-)96.6 %some concernnot evaluable moderateimportant-
clinical improvement 1.32 [0.95, 1.84]> 10%2 studies (2/-)95.3 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.18 [0.87, 1.59]> 10%3 studies (3/-)85.4 %some concernnot evaluable moderateimportant-
death or ventilation 0.92 [0.84, 1.00]< 10%2 studies (2/-)97.2 %some concernnot evaluable moderateimportant-
hospital discharge 1.19 [0.86, 1.64]> 137%2 studies (2/-)85.7 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.81 [0.66, 0.98]< 10%3 studies (3/-)98.4 %some concernnot evaluable moderateimportant-
ICU admission 1.00 [0.13, 7.45]< 10%1 study (1/-)50.0 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 1.35 [0.34, 5.30]< 144%3 studies (3/-)33.4 %some concernnot evaluable moderateimportant-
superinfection 0.91 [0.66, 1.25]< 10%2 studies (2/-)72.5 %some concernnot evaluable moderateimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.